ANG Lifesciences India Limited has announced its board meeting schedule to review quarterly financial performance and conduct other necessary business matters.

Board Meeting Details

The pharmaceutical company has scheduled a board meeting for February 14, 2026, at 05:00 P.M. at its registered office located at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001. The meeting has been convened in accordance with Regulation 29 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

Agenda Items

The board will address several key business matters during the scheduled meeting:

• Consider and approve standalone and consolidated unaudited financial results for the quarter ended December 31, 2025
• Review financial performance for the nine months ended December 31, 2025
• Address any other business matters deemed necessary with the Chairman's permission

Trading Window Restrictions

In compliance with SEBI regulations on insider trading prevention, ANG Lifesciences has implemented specific trading restrictions. The trading window closure began on January 1, 2026, and will remain in effect until 48 hours after the financial results are made public on February 14, 2026. This measure aligns with the company's Code of Conduct for Prevention of Insider Trading and Fair Disclosure of Unpublished Price Sensitive Information.

Company Operations

ANG Lifesciences operates multiple manufacturing facilities across Himachal Pradesh, including units in Baddi and surrounding areas. The company maintains its registered office in Amritsar, Punjab, and conducts pharmaceutical manufacturing operations through its various production units located in Solan district.

ANG Lifesciences India Limited, a pharmaceutical company, has released its financial results for the second quarter of fiscal year 2026, revealing a narrowed loss but decreased revenue compared to the same period last year.

Financial Performance

The company's financial performance for Q2 FY2026 and the first half of the fiscal year is summarized in the table below:

ANG Lifesciences' net loss for Q2 FY2026 stood at ₹79.98 lakh, showing an improvement from the ₹107.39 lakh loss reported in the same quarter of the previous fiscal year. However, revenue from operations declined to ₹2597.05 lakh from ₹3215.88 lakh year-over-year.

For the first half of FY2026, the company reported a net loss of ₹158.71 lakh, compared to ₹383.92 lakh in the corresponding period of the previous year.

Board Meeting and Auditor Appointment

The Board of Directors of ANG Lifesciences India Limited convened on November 14, 2025, to approve the unaudited financial results for Q2 and H1 FY2026. The meeting, which commenced at 05:00 PM, also addressed other corporate matters.

In a significant development, the Board approved the appointment of M/s Shreya Sahu & Associates as the Cost Auditor for the fiscal year 2025-26. This appointment underscores the company's commitment to maintaining robust financial oversight and compliance with regulatory requirements.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standards and have undergone a limited review by the company's statutory auditors, M/s Khurana Sharma & Co. This review process ensures compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ANG Lifesciences continues to navigate challenges in the pharmaceutical sector, as reflected in its financial performance. The company's efforts to streamline operations and reduce losses are evident, though revenue pressures persist.